1037364-36-5 Usage
General Description
4-Bromo-5-fluoro-2-hydroxyaniline is a chemical compound with the molecular formula C6H5BrFNO and a molecular weight of 198.01 g/mol. It is an organic compound consisting of a benzene ring with a bromine atom at position 4, a fluorine atom at position 5, a hydroxyl group at position 2, and an aniline group. 4-Bromo-5-fluoro-2-hydroxyaniline is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and organic materials. It is known for its antimicrobial and anti-inflammatory properties, and it is often utilized in the development of novel drugs and medical treatments. Additionally, 4-Bromo-5-fluoro-2-hydroxyaniline is important in the field of organic chemistry for its use as a reagent or reactant in various chemical reactions and processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1037364-36-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,7,3,6 and 4 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1037364-36:
(9*1)+(8*0)+(7*3)+(6*7)+(5*3)+(4*6)+(3*4)+(2*3)+(1*6)=135
135 % 10 = 5
So 1037364-36-5 is a valid CAS Registry Number.
1037364-36-5Relevant articles and documents
Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model
Pero, Joseph E.,Rossi, Michael A.,Lehman, Hannah D.G.F.,Kelly, Michael J.,Mulhearn, James J.,Wolkenberg, Scott E.,Cato, Matthew J.,Clements, Michelle K.,Daley, Christopher J.,Filzen, Tracey,Finger, Eleftheria N.,Gregan, Yun,Henze, Darrell A.,Jovanovska, Aneta,Klein, Rebecca,Kraus, Richard L.,Li, Yuxing,Liang, Annie,Majercak, John M.,Panigel, Jacqueline,Urban, Mark O.,Wang, Jixin,Wang, Ying-Hong,Houghton, Andrea K.,Layton, Mark E.
, p. 2683 - 2688 (2017/05/29)
Studies on human genetics have suggested that inhibitors of the Nav1.7 voltage-gated sodium channel hold considerable promise as therapies for the treatment of chronic pain syndromes. Herein, we report novel, peripherally-restricted benzoxazoli
